Living-related lung transplantation

Date, Hiroshi

doi:10.21037/jtd.2017.08.152

Cited by 43 publications

(18 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are some advantages of LDLLT over CLT. For example, LDLLT has a shorter duration of ischemia than CLT (10), which appears to contribute to a lower frequency of primary graft failure and airway complications after lung transplantation (11). Chronic lung allograft dysfunction, including BOS, is the major cause of death in CLT patients.…”

Section: Discussionmentioning

confidence: 99%

Twenty-year Follow-up of the First Bilateral Living-donor Lobar Lung Transplantation in Japan

et al. 2019

Self Cite

View full text Add to dashboard Cite

Patients with end-stage lung disease can undergo living-donor lobar lung transplantation (LDLLT), with survival rates improving every year. We herein report the 20-year follow-up findings of the first patient who underwent LDLLT in Japan. A 24-year-old woman with primary ciliary dyskinesia became ventilatordependent after severe respiratory failure and right-sided heart failure following repeated respiratory infections. In 1998, she underwent LDLLT and received her sister's right lower lobe and her mother's left lower lobe. Although the patient required 21 hospitalizations and developed unilateral bronchiolitis obliterans syndrome, she is in good physical condition and lives without restriction at 20 years after undergoing LDLLT.

show abstract

Section: Discussionmentioning

confidence: 99%

Twenty-year Follow-up of the First Bilateral Living-donor Lobar Lung Transplantation in Japan

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Japan in particular has considerable experience with LDLLT with acceptable reported 1-and 5-year survival rates of 70% and 45%, respectively. Nonetheless, even in this experienced centre, donor complications occur in 20-60% of donors, so LDLLT remains reserved for experienced centres with very long waiting times for deceased donor organs [89].…”

Section: Extended Criteria Donorsmentioning

confidence: 99%

Developments in lung transplantation over the past decade

2020

View full text Add to dashboard Cite

With an improved median survival of 6.2 years, lung transplantation has become an increasingly acceptable treatment option for end-stage lung disease. Besides survival benefit, improvement of quality of life is achieved in the vast majority of patients. Many developments have taken place in the field of lung transplantation over the past decade. Broadened indication criteria and bridging techniques for patients awaiting lung transplantation have led to increased waiting lists and changes in allocation schemes worldwide. Moreover, the use of previously unacceptable donor lungs for lung transplantation has increased, with donations from donors after cardiac death, donors with increasing age and donors with positive smoking status extending the donor pool substantially. Use of ex vivo lung perfusion further increased the number of lungs suitable for lung transplantation. Nonetheless, the use of these previously unacceptable lungs did not have detrimental effects on survival and long-term graft outcomes, and has decreased waiting list mortality. To further improve long-term outcomes, strategies have been proposed to modify chronic lung allograft dysfunction progression and minimise toxic immunosuppressive effects. This review summarises the developments in clinical lung transplantation over the past decade.

show abstract

“…Although the first LDLLTs were initially performed in the United States as a measure to reduce waiting list mortality in times of cadaveric donor scarcity, the largest series in LDLLT has repeatedly been reported from Japan over the past years (46).…”

Section: Living-donor Lobar Lung Transplantation (Ldllt)mentioning

confidence: 99%

Lung transplantation for pediatric pulmonary arterial hypertension—quo vadis?

Sommer¹,

Warnecke²

2021

Cardiovasc Diagn Ther

View full text Add to dashboard Cite

In children with pulmonary arterial hypertension, lung transplantation illustrates a feasible treatment option once pharmacological therapy is exhausted. Timing of listing for lung transplantation in children remains difficult since hemodynamic deterioration often occurs abruptly and the time on the waiting list is usually hard to predict. Clear contraindications for lung transplantation are recent history of malignancies as well as irreversible end-organ failure. Generally, patients with pulmonary arterial hypertension in the absence of structural cardiac defects can safely undergo bilateral lung transplantation, combined heart-lung transplantation remains a procedure with a higher perioperative risk and should only be performed in selected cases with irreversible structural defects. Donor selection in recent years shows donors with extended criteria as well as lobar transplantation with good outcome, having the positive effect of broadening of the donor pool. Bridging to lung transplantation with veno-arterial ECMO treatment is feasible and has a good outcome in experienced transplant centers. Surgical considerations should include the risk of hemodynamic decompensation upon anesthesia induction and the need for extracorporeal support pre-, intra-and postoperative. Lung transplantation should be performed on veno-arterial ECMO support with either peripheral (>20 kg) or central cannulation (<20 kg). The surgical transplantation procedure includes the bronchial anastomosis as well as anastomoses of the pulmonary artery and the left atrium.Postoperative prolonged veno-arterial ECMO treatment for the immediate postoperative period allows for left ventricular remodeling given the new hemodynamic circumstances with lower pulmonary vascular resistance. Standard triple immunosuppression in most lung transplant programs currently includes steroids, mycophenolate mofetil and tacrolimus. Survival after pediatric lung transplantation for IPAH is comparable to pediatric lung transplants for other underlying diseases with a 1-year survival of approx. 80% and a 5-year survival of 64-65%. Therefore, evolving techniques in the field of lung transplantation led to overall improved survival prospects in children with end-stage pulmonary vascular disease.

show abstract

Living-related lung transplantation

Cited by 43 publications

References 36 publications

Twenty-year Follow-up of the First Bilateral Living-donor Lobar Lung Transplantation in Japan

Twenty-year Follow-up of the First Bilateral Living-donor Lobar Lung Transplantation in Japan

Developments in lung transplantation over the past decade

Lung transplantation for pediatric pulmonary arterial hypertension—quo vadis?

Contact Info

Product

Resources

About